LH-RH Agonists in the Treatment of Metastatic Breast Cancer: Five Years Experience

  • J. G. M. Klijn
Conference paper

Abstract

Since Schally and Guilemin (1971) unraveled the structure of LH-RH and elucidated its physiology, numerous analogues with pronounced and long-term effects have been synthesized and tested [1–5]. Most of these agents appeared to have a paradoxical antifertility effect during long-term treatment in sufficiently high (supraphysiological) doses. The mose potent of these agents have been applied in experimental and clinical studies. In 1976, De Sombre et al. reported for the first time regression of rat mammary tumors effected by an LH-RH analogue [6]. Since then a number of experimental studies on endocrine and growth-inhibiting effects in rodents with different kinds of tumors have been published [1–5, 7].

Keywords

Estrogen Tamoxifen Progesterone Estradiol Prolactin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289PubMedGoogle Scholar
  2. 2.
    Schally AV, Redding TW (1987) Use of LH-RH analogs for the treatment of prostate cancer: combination therapy and direct effects. In: Klijn JGM, Paridaens R, Foekens J A (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, Vol 18, pp 273–281Google Scholar
  3. 3.
    Corbin A (1982) From contraception to cancer: a review of the therapeutic applications of LH- RH analogues as antitumor agents. Yale J Biol Med 55: 27–47PubMedGoogle Scholar
  4. 4.
    Furr BJA, Nicholson RI (1982) Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer. J Reprod Fertil 64: 529–539PubMedCrossRefGoogle Scholar
  5. 5.
    Sandow J (1983) Clinical applications of LH-RH and its analogues. Clin Endocrinol (Oxf) 18: 571–592CrossRefGoogle Scholar
  6. 6.
    DeSombre ER, Johnson ES, White WF (1976) Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res 36: 3830–3833Google Scholar
  7. 7.
    Danguy A, Legros N, Heuson-Stiennon JA, Pasteels JL, Atassi G, Heuson JC (1977) Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7,12-dimethylbenz(a)an-thracene-induced rat mammary tumours. Histological and endocrine studies. Eur J Cancer 13: 1089–1094PubMedCrossRefGoogle Scholar
  8. 8.
    Eidne KA, Flanagan CA, Miller RP (1985) Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989–992PubMedCrossRefGoogle Scholar
  9. 9.
    Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233PubMedCrossRefGoogle Scholar
  10. 10.
    Miller WR, Scott WN, Fraser HM, Sharpe RM (1987) Direct inhibition of human breast cancer cell growth by an LH-RH agonist. In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, vol 18, pp 357–369Google Scholar
  11. 11.
    Labile F, Belanger A, Dupont A, Emond J, Lacoursiere Y, Monfette G (1984) Combined treatment with LH-RH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet II: 1090Google Scholar
  12. 12.
    Klijn JGM, Paridaens R, Foekens JA (eds) (1987) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, vol 18Google Scholar
  13. 13.
    Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1984) LH-RH-agonist treatment in metastatic prostate carcinoma. Eur J Cancer Clin Oncol 20: 483–493PubMedCrossRefGoogle Scholar
  14. 14.
    Klijn JGM, de Voogt HJ, Schröder FH, de Jong FH (1985) Combined treatment with Buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet II: 493Google Scholar
  15. 15.
    Schröder FJ, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, de Jong FH, Klijn JGM, Matroos AW, de Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 137: 912–919Google Scholar
  16. 16.
    De Jong FH, Schröder FH, Lock MTWT, Debruyne FMJ, De Voogt HJ, Klijn JGM (1987) Effects of long-term treatment with the LH-RH-analogue buserelin on the pituitary-testicular axis in men with prostatic carcinoma (PCA). In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, vol 18, pp 195–202Google Scholar
  17. 17.
    Klijn JGM, de Jong FH (1982) Treatment with a luteinizing hormone-releasing-hormone analogue ( Buserelin) in premenopausal patients with metastatic breast cancer. Lancet I: 1213–1216Google Scholar
  18. 18.
    Klijn JGM, de Jong FH, Blankenstein MA, Docter R, Alexieva-Figusch J, Blonk-van der Wijst J, Lamberts SWJ (1984) Antitumor and endocrine effects of chronic LH-RH agonist ( Buserelin) treatment with or without tamoxifen in premenopausal metastatic breast cancer. Breast Cancer Res Treat 4: 209–220PubMedCrossRefGoogle Scholar
  19. 19.
    EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1516CrossRefGoogle Scholar
  20. 20.
    Klijn JGM, Lamberts SWJ, de Jong FH, Docter R, van Dongen KJ, Birkenhäger JC (1980) The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour. Clin Endocrinol (Oxf) 12: 341–355CrossRefGoogle Scholar
  21. 21.
    Klijn JGM (1984) Long-term LH-RH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatment. Med Oncol Tumor Pharmacother 1: 123–128PubMedGoogle Scholar
  22. 22.
    Klijn JGM, de Jong FH (1984) Long-term treatment with the LH-RH-agonist Buserelin (Hoe 766) for metastatic breast cancer in single and combined drug regimen. In: Labrie F, Belanger A, Dupont A (eds) LH-RH and its analogues, basic and clinical aspects. Excerpta Medica, Amsterdam, pp 425–437Google Scholar
  23. 23.
    Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LH-RH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873PubMedCrossRefGoogle Scholar
  24. 24.
    Klijn JGM, Henkelman MS, Bakker GH (1987) Treatment of premenopausal women with advanced breast cancer or endometriosis with LH-RH analogues. In: Engelsman E (ed) Proceedings of the Symposium on Endocrine-related tumours (May 1985, Noordwijkerhout). Update Siebert publications Ltd, Guildford, pp 160–169Google Scholar
  25. 25.
    Klijn JGM, de Jong FH (1987) Long-term LH-RH-agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, vol 18, pp 343–352Google Scholar
  26. 26.
    Klijn JGM, Foekens JA (1987) Long-term peptide hormone treatment with LH-RH-agonists in metastatic breast cancer. In: Santen R (ed) Proceedings of the International Symposium on Endocrine-dependent breast cancer: critical assessment of recent advances, 14th Int Cancer Congress, Budapest (23rd August 1986) (in press)Google Scholar
  27. 27.
    Manni A, Pearson OH (1980) Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64: 779–785PubMedGoogle Scholar
  28. 28.
    Planting AST, Alexieva-Figusch J, Blonk-van der Wijst J, van Putten WLJ (1985) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69: 363–368PubMedGoogle Scholar
  29. 29.
    Mânni A, Santen R, Harvey H, Lipton A, Max D (1986) Treatment of breast cancer with gonadotropin releasing hormone. Endocr Rev 7: 89–94PubMedCrossRefGoogle Scholar
  30. 30.
    Nicholson RI, Walker KJ, Turkes A, Dyas J, Plowman PN, Williams M, Elston CW, Blarney RW (1987) The British experience with the LH-RH agonist Zoladex (ICI-118630) in the treatment of breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, vol 18, pp 331–343Google Scholar
  31. 31.
    Lippman ME (1985) Growth regulation of human breast cancer. Clin Res 33: 375–382PubMedGoogle Scholar
  32. 32.
    Harvey HA, Lipton A, Max DT (1984) LH-RH analogs for human mammary carcinoma. In: Vickery BH, Nestor JJ, Hafex ESE (eds) LH-RH and its analogues, contraceptive and clinical application. MTP Press, Lancaster, pp 329–338Google Scholar
  33. 33.
    Harvey HA, Lipton A, Max D (1986) LH-RH agonist treatment of breast cancer: a phase II study in the USA. Eur J Cancer Clin Oncol 22: 724Google Scholar
  34. 34.
    Meldrum DR, Tsao Z, Monroe SE, Braunstein GD, Sladek J, Lu JKH, Vale W, Rivier J, Judd HL, Chang R (1984) Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab 58: 755–760PubMedCrossRefGoogle Scholar
  35. 35.
    Nicholson RI, Walker KJ, Turkes A, Dyas J, Plowman PN, Williams M, Blarney RW (1985) Endocrinological and clinical aspects of LH-RH action (ICI-118630) in hormone dependent breast cancer. J Steroid Biochem 23: 843–849PubMedCrossRefGoogle Scholar
  36. 36.
    Hôffken K, Miller B, Fischer P, Becker R, Kurschel E, Scheulen ME, Miller AA, Callies R, Schmidt CG (1986) Buserelin in treatment of premenopausal advanced breast cancer. Eur J Cancer Clin Oncol 22: 746CrossRefGoogle Scholar
  37. 37.
    Mathé G, Keiling R, Vovan ML, Gastiaburu J, Prévôt G, Vannetzel JM, Despax R, Jasmin C, Lévi F, Musset M, Machover D, Misset JL (1986) Phase II trial of D-Trp-6-LH-RH in advanced breast cancer. Eur J Cancer Clin Oncol 22: 723CrossRefGoogle Scholar
  38. 38.
    Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in postmenopausal women with luteinizing hormone releasing hormone (ICI 118 630) therapy. Eur J Cancer Clin Oncol 22: 746CrossRefGoogle Scholar
  39. 39.
    Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15: 171–173PubMedCrossRefGoogle Scholar
  40. 40.
    Blankenstein MA, Henkelman MS, Klijn JGM (1983) An analogue of LH-RH antagonizes the growth-stimulating effect of oestradiol on human breast cancer cells in culture (MCF-7). J Steroid Biochem [Suppl] 19: 95 SGoogle Scholar
  41. 41.
    Blankenstein MA, Henkelman MS, Klijn JGM (1985) Direct inhibitory effect of a luteinizing hormone releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21: 1493–1499PubMedCrossRefGoogle Scholar
  42. 42.
    Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochem Biophys Res Commun 140: 550–556PubMedCrossRefGoogle Scholar
  43. 43.
    Foekens JA, Henkelman MS, Bolt-de Vries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LH-RH analogs on breast and prostatic tumor cells: In: Klijn JGM, Paridaens R, Foekens J A (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. EORTC Monograph Series, Raven Press, New York, vol 18, pp 369–381Google Scholar
  44. 44.
    Wiznitzer I, Benz C (1984) Direct growth inhibiting effects of the prolactin antagonists Buserelin and Pergolide on human breast cancer. Proc Ann Am Assoc Cancer Res 25: 208Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. G. M. Klijn

There are no affiliations available

Personalised recommendations